Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. 1990

Neurology. 2001 Nov;57(10 Suppl 3):S27-33.
No abstract available

Publication types

  • Biography
  • Classical Article
  • Comparative Study
  • Historical Article

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / adverse effects
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / history*
  • Animals
  • Dopamine Agents / adverse effects
  • Dopamine Agents / history*
  • Dopamine Agonists / history*
  • Dopamine Agonists / therapeutic use
  • History, 20th Century
  • Parkinson Disease / history*
  • Parkinson Disease, Secondary / chemically induced
  • Receptors, Dopamine D1 / agonists
  • Receptors, Dopamine D1 / history*
  • Receptors, Dopamine D2 / agonists
  • Receptors, Dopamine D2 / history*
  • Saimiri

Substances

  • Dopamine Agents
  • Dopamine Agonists
  • Receptors, Dopamine D1
  • Receptors, Dopamine D2
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Personal name as subject

  • S Boyce
  • N M Rupniak
  • M J Steventon
  • S D Iversen